Литература
1. Бельмер С.В., Хавкин А. И., Печкуров Д. В. «Функцио- нальные расстройства органов пищеварения у детей (в свете Римских критериев IV)». Методическое по-
собие. Москва, 2016, с. 66–68
2. Foxx-Orenstein A. E. "New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists". Th er Adv Gastroenterol, 2016, Vol. 9(3) 354–375
3. Camilleri, M. "Peripheral mechanisms in irritable bowel syndrome". N Engl J Med 2012367: 1626–1635.
4. Ek, W., Reznichenko, A., Ripke, S., et al. "Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control
cohorts" (он-лайн публикация). 2015, Gut 64: 1774–1782.
5. Grasberger, H., Chang, L., Shih, W., Presson, A., Sayuk, G., Newberry, R. et al. (2013) Identifi cationof a functional TPH1 polymorphism associated with irritable bowel syndrome bowel habit subtypes. Am J. Gastroenterol 108: 1766–1774.
6. Bashashati, M., Rezaei, N., Shafi eyoun, A., et al. "Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis". Neurogastroenterol Motil
2014, 26: 1036–1048.
7. Rana, S., Sharma, S., Sinha, S., Parsad, K., Malik, A. and Singh, K. "Pro infl ammatory and anti-infl ammatory cytokine response in diarrhoeapredominant irritable bowel syndrome patients". Trop Gastroenterol, 2012,
33: 251–256.
8. Walker, M., Talley, N., Prabhakar, M., Pennaneac'h, C., Aro, P., Ronkainen, J. et al. "Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia". Aliment Pharmacol Th er, 2009, 29: 765–773.
9. Vivinus-Nebot, M., Dainese, R., Anty, R., et al. "Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells". Am J. Gastroenterol, 2012, 107: 75–81.
10. Tornblom, H., Van, O., Sadik, R., Abrahamsson, H., Tack, J. and Simren, M. "Colonic transit time and IBS symptoms: what's the link?" Am J Gastroenterol., 2012, 107: 754–760.
11. Larsson, M., Tillisch, K., Craig, A., Engstrom, et al. "Brain responses to visceral stimuli refl ect visceral sensitivity thresholds in patients with irritable bowel syndrome».
Gastroenterology, 2012, 142: 463–472.
12. Tillisch, K., Mayer, E. and Labus, J. "Quantitative metaanalysis identifi es brain regions activated during rectal distension in irritable bowel syndrome". Gastroenterology,
2011, 140: 91–100.
13. Rey de Castro, N., Miller, V., Carruthers, H. and Whorwell, P. "Irritable bowel syndrome: a comparison of subtypes". J Gastroenterol Hepatol, 2015, 30: 279–285.
14. Singh, P., Agnihotri, A., Pathak, M., Shirazi, A., et al. "Psychiatric, somatic and other functional gastrointestinal disorders in patients with irritable bowel syndrome at a tertiary
care center". J Neurogastroenterol Motil, 201218: 324–331.
15. Corsetti M. and Whorwell P. "Th e global impact of IBS: time to think about IBS-specifi c models of care?" Th er Adv Gastroenterol 2017, Vol. 10(9) 727–735.
16. Schwille-Kiuntke J, Enck P, Zendler C et al. "Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confi rmed cases of bacterial infection with
Salmonella or Campylobacter". Neurogastroenterol Motil, 2011; 23: e479–88.
17. Ringel Y, Ringel-Kulka T. "Th e intestinal microbiota and irritable bowel syndrome". J Clin Gastroenterol 2015; 49: S56–9.
18. Malinen E, Rinttila T, Kajander K, et al. "Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR". Am J Gastroenterol,
2005; 100:373–82;
19. Spiller, R.C. "Postinfectious irritable bowel syndrome" Gastroenterol., 2003.Vol. 124, No. 6. – Р. 1662–1671
20. Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinfl ammatory "T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis". Proc Natl
Acad Sci U S A 2011; 108(Suppl 1):4615–22;
21. Atarashi K, Tanoue T, Shima T. et al. "Induction of colonic regulatory T cells by indigenous Clostridium species". Science, 2011; 331:337–41;
22. Konieczna P, Akdis CA, Quigley EM, Shanahan F, O'Mahony L. "Portrait of an immunoregulatory Bifi dobacterium". Gut Microbes 2012; 3:261–6;
23. Brenner D. M., Chey W. D. "Bifi dobacterium infantis 35624: A Novel Probiotic for the Treatment of Irritable Bowel Syndrome" REVIEWS IN GASTROENTEROLOGICAL
DISORDERS, 2009, Vol. 9 N. 1 рр 7–15
24. Quigley E. M., Fried M., Gwee K.-A. et al. World Gastroenterology Organisation Global Guidelines "Irritable Bowel Syndrome: a Global Perspective" Update September 2015, рр. 17–20.
25. F. Guarner, Sanders M. E., Eliakim R. World Gastroenterology Organisation Global Guidelines "Probiotics and prebiotics", February 2017, рр 14.
26. McCarthy J, O'Mahony L, O'Callaghan L, et al. "Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with
cytokine balance". Gut.2003;52: 975–980.
27. Jobin C, Sartor RB. "Th e I-B/NF-B system: a key determinant of mucosal infl ammation and protection". Am J Physiol Cell Physiol. 2000;278: C451-C462.
28. O'Mahony L, McCarthy J, Kelly P, et al. "Lactobacillus and Bifi dobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profi les".
Gastroenterology. 2005;128:541–551.
29. Heaton KW, O'Donnell LJ. "An offi ce guide to whole-gut transit time. Patients' recollection of their stool form". J Clin Gastroenterol. 1994;19:28–30.
30. Whorwell PJ, Altringer L, Morel J, et al. Effi cacy of an encapsulated probiotic Bifi dobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol.
2006;101:1581–1590.
31. Ringel-Kulka T., McRorie J, Ringel Y. "Multi-Center, Double-Blind, Randomized, Placebo-Controlled, ParallelGroup Study to Evaluate the Benefi t of the Probiotic Bifi dobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating". Am J Gastroenterol., 2016; doi: 10.1038/ajg.2016.511
32. Charbonneau D., Gibb R. D., Quigley E. M. "Fecal excretion of Bifi dobacterium infantis 35624 and changes in fecal microbiota aft er eight weeks of oral supplementation
with encapsulated Probiotic". 2013, Gut Microbes 4:3, 201–211
33. Groeger D., O'Mahony L., Murphy E. F., Bourke J. F. et al. "Bifi dobacterium infantis 35624 modulates host infl ammatory processes beyond the gut". Gut Microbes,
2013,4:4, 1–15
34. Altmann F. et al. Plos one. 2016, sept 22, 11(9).